BCL2 and breast cancer: MCL1 is also genetically amplified in 9% of luminal B breast cancers [54] and 54% of TNBCs after treatment with neoadjuvant chemotherapies [28], suggesting that Mcl-1 may represent a more desirable target over Bcl-2/Bcl-xL in some breast cancers.